Clene's presentation by CEO Rob Etherington and CFO Morgan Brown is ... Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and ...

Register for the Conference here. Submit Questions for any of the presenting compa SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) ...

SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage ...

SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical ...

Clene Inc. (NASDAQ:CLNN), a pharmaceutical company with a market capitalization of $30.4 million, announced on Monday it has resolved an outstanding $125,000 debt through the issuance of shares.

SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage ...

Parsons Capital Management Inc. RI purchased a new position in shares of Clene during the 4th quarter worth approximately $194,000. Geode Capital Management LLC lifted its stake in Clene by 52.9% ...

Clene (along with its subsidiaries,“Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial ...